作者: Te-hui W. Chou , Shixia Wang , Pavlo V. Sakhatskyy , Innocent Mboudoudjeck , John M. Lawrence
DOI: 10.1016/J.VIROL.2005.01.035
关键词:
摘要: Inactivated severe acute respiratory syndrome-associated coronavirus (SARS-CoV) has been tested as a candidate vaccine against the re-emergence of SARS. In order to understand efficacy and safety this approach, it is important know antibody specificities generated with inactivated SARS-CoV. current study, panel twelve monoclonal antibodies (mAbs) was established by immunizing Balb/c mice BJ01 strain SARS-CoV isolated from lung tissue SARS-infected Chinese patient. These mAbs could recognize SARS-CoV-infected cells immunofluorescence analysis (IFA). Seven them were mapped specific segments recombinant spike (S) protein: six on S1 subunit (aa 12-798) one S2 797-1192). High neutralizing titers detected two (1A5 2C5) targeting at subdomain S protein 310-535), consistent previous report that segment contains major domain. Some these S-specific able cleaved products in Vero E6 cells. None remaining five either S, N, M, or E antigens ELISA. This study demonstrated preserve immunogenicity including its The relative ease which virions further supports vaccination constructs may also be protect animals perhaps humans. It somewhat unexpected no N-specific identified albeit anti-N IgG easily patients. availability provided potentially useful agents applications therapy, diagnosis, basic research